Treatment Failure and Clinical Stability in Severe Community-Acquired Pneumonia

Raúl Méndez; Paula González-Jiménez; Noé Mengot; Rosario Menéndez

doi:10.1055/s-0043-1778139

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2024; 45(02): 225-236
DOI: 10.1055/s-0043-1778139

Review Article

Treatment Failure and Clinical Stability in Severe Community-Acquired Pneumonia

Authors

Raúl Méndez

¹Pneumology Department, La Fe University and Polytechnic Hospital, Valencia, Spain

²Respiratory Infections, Health Research Institute La Fe (IISLAFE), Valencia, Spain

³Department of Medicine, University of Valencia, Valencia, Spain

⁴Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
Paula González-Jiménez

¹Pneumology Department, La Fe University and Polytechnic Hospital, Valencia, Spain

²Respiratory Infections, Health Research Institute La Fe (IISLAFE), Valencia, Spain

³Department of Medicine, University of Valencia, Valencia, Spain
Noé Mengot

¹Pneumology Department, La Fe University and Polytechnic Hospital, Valencia, Spain

²Respiratory Infections, Health Research Institute La Fe (IISLAFE), Valencia, Spain
Rosario Menéndez

¹Pneumology Department, La Fe University and Polytechnic Hospital, Valencia, Spain

²Respiratory Infections, Health Research Institute La Fe (IISLAFE), Valencia, Spain

³Department of Medicine, University of Valencia, Valencia, Spain

⁴Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain

Abstract

Treatment failure and clinical stability are important outcomes in community-acquired pneumonia (CAP). It is essential to know the causes and risk factors for treatment failure and delay in reaching clinical stability in CAP. The study of both as well as the associated underlying mechanisms and host response are key to improving outcomes in pneumonia.

Keywords

CAP - inflammatory-immune response - microbiologic treatment

Volltext

Referenzen

References
1 Martin-Loeches I, Torres A, Nagavci B. et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J 2023; 61 (04) 2200735
2 Ferrer M, Travierso C, Cilloniz C. et al. Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS One 2018; 13 (01) e0191721
3 Kolditz M, Ewig S, Klapdor B. et al; CAPNETZ study group. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax 2015; 70 (06) 551-558
4 Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137 (03) 552-557
5 Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest 2007; 132 (04) 1348-1355
6 Finch S, Chalmers JD. Brief clinical review: non-responding pneumonia. EMJ Respir 2014; (e-pub ahead of print).
7 Arancibia F, Ewig S, Martinez JA. et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162 (01) 154-160
8 Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164 (05) 502-508
9 Menéndez R, Torres A, Zalacaín R. et al; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59 (11) 960-965
10 Menéndez R, Cavalcanti M, Reyes S. et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63 (05) 447-452
11 Hoogewerf M, Oosterheert JJ, Hak E, Hoepelman IM, Bonten MJM. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect 2006; 12 (11) 1097-1104
12 Garcia-Vidal C, Carratalà J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med 2009; 30 (02) 154-160
13 Mandell LA, Wunderink RG, Anzueto A. et al; Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2, Suppl 2): S27-S72
14 Montravers P, Fagon JY, Chastre J. et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147 (01) 38-44
15 Halm EA, Fine MJ, Marrie TJ. et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279 (18) 1452-1457
16 Ortqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990; 97 (03) 576-582
17 Albin OR, Henig O, Patel TS. et al. Clinical implications of microbiologic treatment failure in the setting of clinical cure of bacterial pneumonia. Clin Infect Dis 2020; 71 (12) 3033-3041
18 Ewig S, Ruiz M, Torres A. et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae . Am J Respir Crit Care Med 1999; 159 (06) 1835-1842
19 Jacobs JA, De Brauwer EIGB, Ramsay G. et al. Detection of non-infectious conditions mimicking pneumonia in the intensive care setting: usefulness of bronchoalveolar fluid cytology. Respir Med 1999; 93 (08) 571-578
20 Weyers CM, Leeper KV. Nonresolving pneumonia. Clin Chest Med 2005; 26 (01) 143-158
21 Kuru T, Lynch III JP. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20 (03) 623-651
22 Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am 2001; 85 (06) 1511-1530 , xi
23 Dinh A, Duran C, Ropers J. et al; Pneumonia Short Treatment (PTC) Study Group. Factors associated with treatment failure in moderately severe community-acquired pneumonia: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2021; 4 (10) e2129566
24 Lopes M, Alves Silva G, Nogueira RF. et al. Incidence of antibiotic treatment failure in patients with nursing home-acquired pneumonia and community acquired pneumonia. Infect Dis Rep 2021; 13 (01) 33-44
25 Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. BMC Pulm Med 2019; 19 (01) 179
26 Oster G, Berger A, Edelsberg J, Weber DJ. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. J Med Econ 2013; 16 (06) 809-819
27 Capelastegui A, España Yandiola PP, Quintana JM. et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest 2009; 136 (04) 1079-1085
28 Liapikou A, Cillóniz C, Gabarrús A. et al. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. Eur Respir J 2016; 48 (01) 257-261
29 Aliberti S, Brambilla AM, Chalmers JD. et al. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res 2014; 15 (01) 27
30 Ryan K, Karve S, Peeters P. et al. The impact of initial antibiotic treatment failure: real-world insights in healthcare-associated or nosocomial pneumonia. J Infect 2018; 77 (01) 9-17
31 Ewig S, Kolditz M, Pletz MW, Chalmers J. Healthcare-associated pneumonia: is there any reason to continue to utilize this label in 2019?. Clin Microbiol Infect 2019; 25 (10) 1173-1179
32 Ott SR, Hauptmeier BM, Ernen C. et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J 2012; 39 (03) 611-618
33 Bermejo-Martin JF, Almansa R, Martin-Fernandez M, Menendez R, Torres A. Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. Lancet Respir Med 2017; 5 (12) e35-e36
34 Jarczak D, Nierhaus A. Cytokine storm-definition, causes, and implications. Int J Mol Sci 2022; 23 (19) 11740
35 Brinkmann V, Reichard U, Goosmann C. et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303 (5663) 1532-1535
36 Cheng OZ, Palaniyar N. NET balancing: a problem in inflammatory lung diseases. Front Immunol 2013; 4: 1
37 Grover SP, Mackman N. Neutrophils, NETs, and immunothrombosis. Blood 2018; 132 (13) 1360-1361
38 Ebrahimi F, Giaglis S, Hahn S. et al. Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. Eur Respir J 2018; 51 (04) 1701389
39 Bermejo-Martin JF, Cilloniz C, Mendez R. et al; NEUMONAC group. Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. EBioMedicine 2017; 24: 231-236
40 Méndez R, Menéndez R, Amara-Elori I. et al. Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. J Infect 2019; 78 (06) 423-431
41 de la Torre MC, Palomera E, Serra-Prat M. et al. IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia. J Crit Care 2016; 35: 115-119
42 Menéndez R, Méndez R, Aldás I. et al. Community-acquired pneumonia patients at risk for early and long-term cardiovascular events are identified by cardiac biomarkers. Chest 2019; 156 (06) 1080-1091
43 Martin-Loeches I, Valles X, Menendez R. et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study. Respir Res 2014; 15 (01) 75
44 Ruiz-González A, Falguera M, Porcel JM. et al. C-reactive protein for discriminating treatment failure from slow responding pneumonia. Eur J Intern Med 2010; 21 (06) 548-552
45 Méndez R, Menéndez R, Cillóniz C. et al. Initial inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms. Am J Respir Crit Care Med 2018; 198 (03) 370-378
46 Pereira JM, Laszczyńska O, Azevedo A. et al. Early prediction of treatment failure in severe community-acquired pneumonia: the PRoFeSs score. J Crit Care 2019; 53: 38-45
47 Corrales-Medina VF, Alvarez KN, Weissfeld LA. et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015; 313 (03) 264-274
48 Aldás I, Menéndez R, Méndez R. et al; Grupo NEUMONAC, Anexo. Grupo NEUMONAC. Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. Arch Bronconeumol (Engl Ed) 2020; 56 (09) 551-558
49 Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T. German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182 (11) 1426-1434
50 Darie AM, Khanna N, Jahn K. et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. Lancet Respir Med 2022; 10 (09) 877-887
51 Kao KC, Chang KW, Chan MC. et al; TSIRC (Taiwan Severe Influenza Research Consortium). Predictors of survival in patients with influenza pneumonia-related severe acute respiratory distress syndrome treated with prone positioning. Ann Intensive Care 2018; 8 (01) 94
52 Bryner B, Miskulin J, Smith C. et al. Extracorporeal life support for acute respiratory distress syndrome due to severe Legionella pneumonia. Perfus (United Kingdom) 2014; (e-pub ahead of print).
53 Pappalardo F, Pieri M, Greco T. et al; Italian ECMOnet. Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: the ECMOnet score. Intensive Care Med 2013; 39 (02) 275-281
54 Naqvi A, Kapoor S, Pradhan M, Dicpinigaitis PV. Outcomes of severe Legionella pneumonia requiring extracorporeal membrane oxygenation (ECMO). J Crit Care 2021; 61: 103-106
55 Chan MC, Hsu JY, Liu HH. et al. Effects of prone position on inflammatory markers in patients with ARDS due to community-acquired pneumonia. J Formos Med Assoc 2007; 106 (09) 708-716
56 Park C, Na SJ, Chung CR, Cho YH, Suh GY, Jeon K. Community versus hospital-acquired pneumonia in patients requiring extracorporeal membrane oxygenation. Ther Adv Respir Dis 2019; 13: 1753466618821038
57 Richard C, Argaud L, Blet A. et al. Extracorporeal life support for patients with acute respiratory distress syndrome: report of a Consensus Conference. Ann Intensive Care 2014; 4: 15
58 Torres A, Sibila O, Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313 (07) 677-686
59 Abelenda-Alonso G, Rombauts A, Gudiol C. et al. Impact of comprehensive molecular testing to reduce antibiotic use in community-acquired pneumonia (RADICAP): a randomised, controlled, phase IV clinical trial protocol. BMJ Open 2020; 10 (08) e038957
60 Torres A, Cilloniz C, Niederman MS. et al. Pneumonia. Nat Rev Dis Prim 2021; (e-pub ahead of print).
61 Bassetti M, Magnè F, Giacobbe DR, Bini L, Vena A. New antibiotics for Gram-negative pneumonia. Eur Respir Rev 2022; 31 (166) 220119
62 Lisboa T, Blot S, Waterer GW. et al. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest 2009; 135 (01) 165-172
63 Otto GP, Sossdorf M, Claus RA. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011; 15 (04) R183
64 Engel MF, Postma DF, Hulscher MEJL. et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur Respir J 2013; 41 (01) 123-130
65 Menéndez R, Torres A, Rodríguez de Castro F. et al; Neumofail Group. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39 (12) 1783-1790
66 Aliberti S, Peyrani P, Filardo G. et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest 2011; 140 (02) 482-488
67 Ramirez JA, Vargas S, Ritter GW. et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159 (20) 2449-2454
68 Arnold FW, Brock GN, Peyrani P. et al; CAPO authors. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2010; 104 (11) 1736-1743
69 Arnold F, LaJoie A, Marrie T. et al; Community-Acquired Pneumonia Organization. The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. Int J Tuberc Lung Dis 2006; 10 (07) 739-743
70 Iqbal N, Irfan M, Zubairi ABS, Awan S, Khan JA. Association of hypercapnia on admission with increased length of hospital stay and severity in patients admitted with community-acquired pneumonia: a prospective observational study from Pakistan. BMJ Open 2017; 7 (06) e013924
71 Takada K, Matsumoto S, Kojima E. et al. Predictors and impact of time to clinical stability in community-acquired pneumococcal pneumonia. Respir Med 2014; 108 (05) 806-812
72 Bordón J, Peyrani P, Brock GN. et al; CAPO Study Group. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest 2008; 133 (03) 618-624
73 Menéndez R, España PP, Pérez-Trallero E. et al. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. Vaccine 2017; 35 (39) 5264-5270
74 Garin N, Felix G, Chuard C. et al. Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia. PLoS One 2016; 11 (06) e0157350
75 Peyrani P, Wiemken TL, Metersky ML. et al. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization. Infect Dis (Lond) 2018; 50 (01) 13-20
76 Garin N, Genné D, Carballo S. et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014; 174 (12) 1894-1901
77 Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 2016; 315 (06) 593-602
78 Marti C, John G, Genné D. et al. Time to antibiotics administration and outcome in community-acquired pneumonia: Secondary analysis of a randomized controlled trial. Eur J Intern Med 2017; 43: 58-61
79 Fally M, Israelsen S, Benfield T, Tarp B, Ravn P. Time to antibiotic administration and patient outcomes in community-acquired pneumonia: results from a prospective cohort study. Clin Microbiol Infect 2021; 27 (03) 406-412
80 Silber SH, Garrett C, Singh R. et al. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 2003; 124 (05) 1798-1804
81 Daifuku R, Movahhed H, Fotheringham N, Bear MB, Nelson S. Time to resolution of morbidity: an endpoint for assessing the clinical cure of community-acquired pneumonia. Respir Med 1996; 90 (10) 587-592
82 Blasi F, Ostermann H, Racketa J, Medina J, McBride K, Garau J. REACH study group. Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study. Respir Res 2014; 15 (01) 6
83 Menéndez R, Martinez R, Reyes S. et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax 2009; 64 (11) 987-992
84 Uranga A, España PP, Bilbao A. et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 2016; 176 (09) 1257-1265
85 Dinh A, Ropers J, Duran C. et al; Pneumonia Short Treatment (PTC) Study Group. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet 2021; 397 (10280): 1195-1203
86 Israelsen SB, Fally M, Tarp B, Kolte L, Ravn P, Benfield T. Short-course antibiotic therapy for hospitalized patients with early clinical response in community-acquired pneumonia: a multicentre cohort study. Clin Microbiol Infect 2022;
87 Menéndez R, Cilloniz C, España PP. et al. Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. Arch Bronconeumol 2020; 56: 1-10
88 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
89 Akram AR, Chalmers JD, Taylor JK, Rutherford J, Singanayagam A, Hill AT. An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect 2013; 19 (12) 1174-1180
90 Cortoos PJ, Gilissen C, Laekeman G. et al. Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia. Scand J Infect Dis 2013; 45 (03) 219-226
91 Corticosteroids in Community-Acquired Pneumonia. Corticosteroids in community-acquired pneumonia. JAMA 2020; 323 (09) 887-888
92 Briel M, Spoorenberg SMC, Snijders D. et al; Ovidius Study Group, Capisce Study Group, STEP Study Group. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis 2018; 66 (03) 346-354
93 Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: a systematic review, meta-analysis, and meta-regression of randomized control trials. Chest 2023; 163 (03) 484-497
94 Sexton TR, Zhang G, Macaulay TE. et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl Sci 2018; 3 (04) 435-449
95 Rögnvaldsson KG, Bjarnason A, Kristinsson K. et al. Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia: a long-term nationwide study. J Intern Med 2022; 292 (02) 321-332
96 Falcone M, Russo A, Shindo Y. et al. A hypothesis-generating study of the combination of aspirin plus macrolides in patients with severe community-acquired pneumonia. Antimicrob Agents Chemother 2019; 63 (02) e01556-e18
97 Sapey E, Patel JM, Greenwood H. et al. Simvastatin improves neutrophil function and clinical outcomes in pneumonia. A pilot randomized controlled clinical trial. Am J Respir Crit Care Med 2019; 200 (10) 1282-1293
98 de la Torre MC, Torán P, Serra-Prat M. et al. Serum levels of immunoglobulins and severity of community-acquired pneumonia. BMJ Open Respir Res 2016; 3 (01) e000152
99 Welte T, Dellinger RP, Ebelt H. et al. Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation—the CIGMA study. Respir Med 2015; 109 (06) 758-767
100 Welte T, Dellinger RP, Ebelt H. et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med 2018; 44 (04) 438-448